Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0002042077-25-000004
Filing Date
2025-09-26
Accepted
2025-09-26 11:52:12
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 4658
  Complete submission text file 0002042077-25-000004.txt   6214
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Subject) CIK: 0000876343 (see all company filings)

EIN.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-42290 | Film No.: 251347631
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 6222 INDIANWOOD TR. BLOOMFIELD HILLS MI 48301
Business Address
Chernett Jorey (Filed by) CIK: 0002042077 (see all company filings)

Type: SCHEDULE 13G